乳腺癌中的 Toll 样受体 9。
Toll-like receptor 9 in breast cancer.
机构信息
Turku Centre for Biotechnology, University of Turku and Åbo Akademi University , Turku , Finland.
Department of Pathology, Lapland Central Hospital , Rovaniemi , Finland ; Division of Hematology-Oncology, Department of Medicine, University of Alabama at Birmingham , Birmingham, AL , USA ; Comprehensive Cancer Center, University of Alabama at Birmingham , Birmingham, AL , USA.
出版信息
Front Immunol. 2014 Jul 22;5:330. doi: 10.3389/fimmu.2014.00330. eCollection 2014.
Toll-like receptor 9 (TLR9) is a cellular DNA receptor of the innate immune system. DNA recognition via TLR9 results in an inflammatory reaction, which eventually also activates a Th1-biased adaptive immune attack. In addition to cells of the immune system, TLR9 mRNA and protein are also widely expressed in breast cancer cell lines and in clinical breast cancer specimens. Although synthetic TLR9-ligands induce cancer cell invasion in vitro, the role of TLR9 in cancer pathophysiology has remained unclear. In the studies conducted so far, tumor TLR9 expression has been shown to have prognostic significance only in patients that have triple-negative breast cancer (TNBC). Specifically, high tumor TLR9 expression predicts good prognosis among TNBC patients. Pre-clinical studies suggest that TLR9 expression may affect tumor immunophenotype and contribute to the immunogenic benefit of chemotherapy. In this review, we discuss the possible contribution of tumor TLR9 to the pathogenesis and treatment responses in breast cancer.
Toll 样受体 9（TLR9）是先天免疫系统的一种细胞 DNA 受体。TLR9 通过 DNA 识别会引发炎症反应，最终也会激活偏向 Th1 的适应性免疫攻击。除了免疫系统细胞外，TLR9mRNA 和蛋白在乳腺癌细胞系和临床乳腺癌标本中也广泛表达。尽管合成的 TLR9 配体在体外诱导癌细胞侵袭，但 TLR9 在癌症病理生理学中的作用仍不清楚。在迄今为止进行的研究中，仅在患有三阴性乳腺癌（TNBC）的患者中，肿瘤 TLR9 表达被证明具有预后意义。临床前研究表明，TLR9 表达可能影响肿瘤免疫表型，并有助于化疗的免疫获益。在这篇综述中，我们讨论了肿瘤 TLR9 对乳腺癌发病机制和治疗反应的可能贡献。
Zotero 插件